It was also found during the 8-week period that there were high incidences of inflammation-related adverse events in both the pneumonia and non-pneumonia groups (fever 89.8% vs. 19.6, CRP elevation 73.5% vs. 9.1%, respectively). Here, CRP is linked to pneumonia.